Parkinson’s and ALS Reviewed

NI Research has released the November/December issue of NeuroPerspective, which features our comprehensive reviews for two major neurodegenerative disorders: Parkinson’s and ALS. These reviews include a consideration of the current thinking around pathophysiology and therapeutic targets, including the protein aggregates considered to be associated with these disorders: Alpha-synuclein, TDP-43, and c9orf72.  Neuroinflammation, GBA as a target, the gut-brain microbiome, and other mechanisms of current interest are included. Progress in the delineation of biomarkers and models is discussed.

The Parkinson’s review includes 140+ programs, including PD development programs from AbbVie, AC Immune, Affiris, Allergan/Lysosomal, Biogen, Cantabio,  Biogen, Denali, Genentech, ImStar, Intra-Cellular, JNJ, Lundbeck, Minerva, Neurocrine,  Prothena/Roche, and Voyager. The ALS review includes 75+ programs, including those from AB Science, Aquinnah Pharma, Arrakis, Astellas/Cytokinetics, Biogen/Ionis, Califia, Denali/Incro, Gladstone Institute, ImStar, Iron Horse Therapeutics, Locana, Neuraltus, Neurimmune, Voyager Therapeutics, and Wave Life Sciences

Cantabio Pharma is the focus of the Company Review. Sidebars include a more detailed look at the failure of the SAGE brexanolone trial in SRSE; ethical issues around Avanir’s marketing of Nuedexta; and Axovant’s failure in Alzheimer’s. 65 pages.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. The November/December issue’s review of PD and ALS is the continuation of a two-issue sequence on neurodegeneration, with the September/October 2017 issue having comprehensively covered Alzheimer’s.

NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.  A one-year (1-5 user) subscription to NeuroPerspective is $2600. A 6-10 user subscription is $4630. Other customized userbase and  startup pricing options are available. The Parkinson’s/ALS  review issue of NeuroPerspective is available as a single-issue purchase for $600.

NI Research has also released the 2017-18 edition of NeuroLicensing, which comprehensively reviews current licensing trends in the CNS area, and assesses large and midsize pharma companies in terms of their licensing agendas and performance.